PCN69 COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER- A UK PERSPECTIVE
May 1, 2009, 00:00 AM
10.1016/S1098-3015(10)73306-4
https://www.valueinhealthjournal.com/article/S1098-3015(10)73306-4/fulltext
Section Title :
Section Order :
732
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73306-4&doi=10.1016/S1098-3015(10)73306-4